Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus Journal Article
| Authors: | Dittmer, D. P.; Krown, S. E. |
| Article Title: | Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus |
| Abstract: | PURPOSE OF REVIEW: To summarize major recent findings on the biology of human herpesvirus-8, i.e. Kaposi's sarcoma-associated herpesvirus, and the implications of these findings for Kaposi's sarcoma treatment. RECENT FINDINGS: Although reduced in incidence in developed countries since the introduction of highly active antiretroviral therapy, Kaposi's sarcoma incidence is still markedly increased in HIV-infected patients in resource-rich areas of the world and is a major complication among HIV-infected individuals in sub-Saharan Africa. The Akt/mammalian target of rapamycin pathway has emerged as a major driving force in Kaposi's sarcoma. In addition, the roles of p53, the Kaposi's sarcoma-associated herpesvirus viral cyclin and nuclear factor-κB in the development and progression of Kaposi's sarcoma are being further clarified, and therapeutic agents are being developed that may target these pathogenetic mechanisms. New Kaposi's sarcoma treatments should be considered that target the molecular interface between virus and host. SUMMARY: The growing knowledge of Kaposi's sarcoma biology provides multiple opportunities for rational targeted therapies. Further research is needed to better understand the mechanisms by which Kaposi's sarcoma develops and to develop therapeutic strategies that prevent resistance to treatment. © 2007 Lippincott Williams & Wilkins, Inc. |
| Keywords: | protein kinase b; unclassified drug; clinical trial; disease course; pathogenesis; review; sorafenib; bevacizumab; doxorubicin; sunitinib; cancer growth; nonhuman; side effect; antineoplastic agents; alpha interferon; human immunodeficiency virus infection; antineoplastic agent; imatinib; bortezomib; incidence; immunoglobulin enhancer binding protein; nutlin 3; angiogenesis; protein p53; arthralgia; drug delivery systems; depression; drug mechanism; developed country; mammal; hemolytic anemia; flu like syndrome; antiretrovirus agent; highly active antiretroviral therapy; kaposi sarcoma; sarcoma, kaposi; cycline; drug dose increase; roscovitine; tetracycline; proteinase inhibitor; rapamycin; cyclosporin; clinical trials; comprehension; human herpesvirus 8; herpesvirus 8, human; host; protein kinase b inhibitor; africa; recombinant alpha2b interferon; indinavir; human immunodeficiency virus infected patient; rna directed dna polymerase inhibitor; ritonavir; nelfinavir; kaposi's sarcoma; akt/mammalian target of rapamycin; kaposi's sarcoma herpesvirus; viral cyclin; 4 dedimethylaminosancycline; hdm2 antagonist; im 862; recombinant interleukin 12 |
| Journal Title: | Current Opinion in Oncology |
| Volume: | 19 |
| Issue: | 5 |
| ISSN: | 1040-8746 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2007-09-01 |
| Start Page: | 452 |
| End Page: | 457 |
| Language: | English |
| DOI: | 10.1097/CCO.0b013e3281eb8ea7 |
| PUBMED: | 17762570 |
| PROVIDER: | scopus |
| PMCID: | PMC2855645 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 16" - "Export Date: 17 November 2011" - "CODEN: CUOOE" - "Source: Scopus" |
